JPRN-UMIN000012793
Completed
未知
Studies on the predictive factors of treatment outcome after intravitreal injection of Lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (CRVO) - Effect of ranibizumab in eyes with macular edema associated with CRVO
Ophthalmology, Mie University Hospital0 sites30 target enrollmentJanuary 10, 2014
ConditionsCentral retinal vein occlusion
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Central retinal vein occlusion
- Sponsor
- Ophthalmology, Mie University Hospital
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Any history of previous treatments for CRVO
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A study of factors which predicts the therapeutic effect of acotiamide on abdominal symptoms in patients with Functional dyspepsia.Functional dyspepsiaJPRN-UMIN000036265Akita University Graduate School of Medicine Department of Gastroenterology and Neurology200
Completed
Not Applicable
Prognostic Factors for treatment and follow-up of patients after colorectal surgerychemo- en radiotherapeutische voorbehandelingseffecten op maagdarm neoplasmatacolorectal cancergut cancer1001799110017998NL-OMON31685Atrium Medisch Centrum400
Completed
Phase 3
Study on indicators for predicting the therapeutic effect of SGLT2 inhibitors under actual clinical practice in T2DM patientstype 2 diabetes mellitudsJPRN-UMIN000032848Osaki Citizen Hospital100
Completed
Not Applicable
A preliminary study of a predictor of treatment response to transcranial magnetic stiumulation in treatment-resistant depressioJPRN-UMIN000026122Teikyo University15
Completed
Not Applicable
To know the outcome of specially prepared blood derivative on treatment of decay of bone due to certain cancer medicines commonly termed as MRONJ (Medicine related osteonecrosis of jaw)Health Condition 1: null- malignant disease and bony metastases receiving antiresorptives namely Zolendronate, Clorandonate, Palmidronate, Ebandronate and DenosumabCTRI/2017/09/009615no269